What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?

被引：25

作者：

Benjamin, RJ ^{[1
]}

Anderson, KC ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Partners Canc Care, Boston, MA USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2002年 / 42卷 / 02期

关键词：

platelets; thrombocytopenia; prophylactic transfusion; hemorrhage; chemotherapy; leukemia; stem cell transplantation;

D O I：

10.1016/S1040-8428(01)00182-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Platelet transfusion therapy is an integral part of modern oncological practice and is used to treat hemorrhage associated with thrombocytopenia. More commonly, platelets are transfused to prevent hemorrhage in thrombocytopenic patients. Conventional wisdom has suggested a threshold for prophylactic transfusion of < 20 x 10(9)/l. Many studies now support the safety of more conservative transfusion regimes that reduce patient exposure to donors and conserve precious resources, without an increase in risk of hemorrhage. This review presents the data to support the use of a prophylactic transfusion threshold of < 10 x 10(9)/l in patients without risk factors for hemorrhage and who have ready access to emergent medical care. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：163 / 171

页数：9

共 50 条

[1] BLEEDING DUE TO THROMBOCYTOPENIA IN ACUTE LEUKEMIAS AND REEVALUATION OF THE PROPHYLACTIC PLATELET TRANSFUSION POLICY [J].

ADERKA, D ;

PRAFF, G ;

SANTO, M ;

WEINBERGER, A ;

PINKHAS, J .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1986, 291 (03) :147-151

[2]

*AM ASS BLOOD BANK, 1996, ASS B AM ASS BLOOD B, V966

[3] CONTROVERSIES IN TRANSFUSION MEDICINE - PROPHYLACTIC PLATELET TRANSFUSION THERAPY - PRO [J].

BAER, MR ;

BLOOMFIELD, CD .

TRANSFUSION, 1992, 32 (04) :377-380

[4] INCIDENCE OF HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH CANCER [J].

BELT, RJ ;

LEITE, C ;

HAAS, CD ;

STEPHENS, RL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (24) :2571-2574

[5]

BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V257, P1777

[6] A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation [J].

Bernstein, SH ;

Nademanee, AP ;

Vose, JM ;

Tricot, G ;

Fay, JW ;

Negrin, RS ;

DiPersio, J ;

Rondon, G ;

Champlin, R ;

Barnett, MJ ;

Cornetta, K ;

Herzig, GP ;

Vaughan, W ;

Geils, G ;

Keating, J ;

Messner, H ;

Wolff, SN ;

Miller, KB ;

Linker, C ;

Cairo, M ;

Hellmann, S ;

Ashby, M ;

Stryker, S ;

Nash, RA .

BLOOD, 1998, 91 (09) :3509-3517

[7]

BEUTLER E, 1993, BLOOD, V81, P1411

[8] Final statement from the consensus conference on platelet transfusion [J].

Contreras, M .

TRANSFUSION, 1998, 38 (08) :796-797

[9] The relation of blood platelets to hemorrhagic disease - Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion [J].

Duke, WW .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1910, 55 :1185-1192

[10]

DUTCHER JP, 1984, CANCER, V53, P557, DOI 10.1002/1097-0142(19840201)53:3<557::AID-CNCR2820530331>3.0.CO

← 1 2 3 4 5 →